Pre-surgery radiation plus immunotherapy for mucosal melanoma
Part of Cancer, Ear, nose & throat clinical trials.
This Phase 2 trial tests giving radiation and immunotherapy before surgery for mucosal melanoma in the nose/sinuses or rectum. It may help shrink the tumor and improve outcomes while aiming to control the disease locally and in nearby areas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed mucosal melanoma tumor seen on exam or imaging (nose/sinuses or rectum).
- Your scans show no distant spread (no metastases).
- You are planning to receive a combination immunotherapy regimen (such as ipilimumab and nivolumab, or nivolumab and relatlimab).
- You are age 18 or older and can understand and sign informed consent.
- Your health status is good enough for treatment (ECOG 3 or less).
- You cannot have had prior radiation to the same area where the study radiation would be given.
- If you could get pregnant (or if you have a partner who could), you must agree to reliable birth control during the study and after radiation (RT is harmful to a pregnancy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of three immunotherapy drugs before surgery can help shrink melanoma and improve outcomes. It is for people whose melanoma can be surgically removed, and the goal is to see if this approach is safe and effective.
This trial tests a combination of chemo drugs (paclitaxel polymersomes, carboplatin) and an immunotherapy (adebelimab) before surgery for people with mucosal melanoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial studies whether giving pembrolizumab (an immunotherapy) together with a targeted form of radiation can help after surgery for mucosal melanoma. It aims to lower the chance of the cancer coming back and improve outcomes in people whose tumor was removed.
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
This trial tests two drugs given before surgery to shrink melanoma that has spread to lymph nodes. The goal is to see if this combination helps remove the cancer more effectively.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
Hear when a new Sinonasal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.